February 1, 2025 — MediLink Therapeutics (“MediLink”), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for YL217, an investigational antibody-drug conjugate (ADC) developed by MediLink. YL217 is the 11th ADC candidate entering into clinical stage developed based on MediLink’s proprietary TMALIN® technology platform.

About YL217

YL217 is an antibody-drug-conjugate with a novel target, primarily developed for gastrointestinal tumors. The targeted protein is specifically expressed in gastric cancer, colorectal cancer, pancreatic cancer, and hepatocellular carcinoma. High expression of the target is associated with metastatic progression in different cancers that mainly originate from gastrointestinal tracts, and is upregulated in late-stage, highly-differentiated tumors. YL217 has been developed by utilizing MediLink's Tumor Microenvironment Activable LINker-payload (TMALIN®) technology platform. The phase I trial for YL217 is in preparation.

About MediLink

MediLink Therapeutics, founded in 2020, is a clinical stage biotech company dedicated to developing innovative conjugated drugs for global patients. MediLink has developed a variety of innovative and proprietary linker-payload systems with different mechanisms of action. Among them, the established tumor microenvironment-activatable toxin-linker platform (TMALIN®) technology platform currently has enabled 10 ADC candidates entering clinical stage in the US and China. The goal of the company is to provide better treatment options for global patients and address unmet medical needs. The company is located in Suzhou and Boston, with subsidiaries in Shanghai and Singapore.